Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease.
Kidney dialysis patients taking a diabetes medication showed 17% lower death rates, suggesting broader heart and kidney protective benefits in this vulnerable population.
This PubMed record examines Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease. The abstract's reported finding is: Among incident ICHD patients, GLP-1RA use was independently associated with a 9% lower hospitalization rate and a 17% lower mortality rate.
What the study was
- Study design
- Retrospective observational study
- Population
- Human participants; details in abstract
- Category
- Public Health
- Maturity
- Exploratory
- Journal
- Clinical journal of the American Society of Nephrology : CJASN
Why it surfaced
Retained as a 8/10 high-priority match for Cardiovascular-metabolic; scoring is conservative because triage used the PubMed abstract without full-text review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.